Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Illumina Inc ILMN

Illumina, Inc. is a provider of sequencing and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.


NDAQ:ILMN - Post by User

<< Previous
Bullboard Posts
Next >>
Post by R_J_on Feb 02, 2020 7:47am
116 Views
Post# 30630435

End of Month - January 2020

End of Month - January 2020End of the Month Report for January 2020 for Illumina Inc.
-
ILMN closed on 01/31/2020 at US$ 290.07
ILMN closed on 12/31/2019 at US$ 331.74
-
This is a 12.6% loss, a US$ 41.67 loss, for Janury
-
S&P 500 Index, @ 3225.5 lost 0.5% in January. [7.1% above its MA(200) @ 3011.8]
-
Two Hundred Day Moving Average [MA(200)] stuff.
ILMN's  MA(200) ended January at US$313.24
ILMN is now 7.4% below its MA(200).
-
News Releases on the ILMN Website in January

-
Jan 29, 2020     
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019
-
https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=005f3f8e-567b-478a-8e15-609e45bef4d2
-
Jan 13, 2020     
Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020
-
Jan 13, 2020     
Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics
-
Jan 13, 2020     
Illumina and Roche Partner to Broaden Patient Access to Genomic Testing
-
Jan 10, 2020     
Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom
-
Jan 2, 2020     
Illumina and Pacific Biosciences Announce Termination of Merger Agreement
-
Who is in charge?
Francis A. DeSouza, CEO
-
RJ
<< Previous
Bullboard Posts
Next >>